Nanochip could spot lymphoma relapse early

NCT ID NCT03656835

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This pilot study is testing a nanochip (ILN biochip) to see if it can monitor how well treatment is working and detect relapse in people with diffuse large B-cell lymphoma. About 73 patients will provide blood samples for the chip to analyze genetic markers. The goal is to find out if this technology can predict treatment outcomes and catch a return of the cancer sooner than standard methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nanochip technology (ILN biochip)
What this could lead to
If successful, this nanochip could help doctors track how well lymphoma treatment is working and catch a relapse earlier than current methods.
What could go wrong
This is a small pilot study with only 73 participants, so results may not apply to everyone. The technology is still experimental and needs much more testing before it could be used in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.